{
    "status": "ok",
    "totalResults": 176,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": null,
            "title": "Analyst Report: AbbVie Inc",
            "description": "Find the latest AbbVie Inc. (ABBV) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance",
            "url": "https://finance.yahoo.com/research/reports/ARGUS_3610_AnalystReport_1695207879000/",
            "urlToImage": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo.png",
            "publishedAt": "2023-09-20T11:04:39Z",
            "content": "AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&amp;P 500.\r\nSu\u2026 [+188 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Science Daily"
            },
            "author": null,
            "title": "Newfound mechanism suggests drug combination could starve pancreatic cancer",
            "description": "A study found that a new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel.",
            "url": "https://www.sciencedaily.com/releases/2023/10/231009191634.htm",
            "urlToImage": "https://www.sciencedaily.com/images/scidaily-icon.png",
            "publishedAt": "2023-10-09T23:16:34Z",
            "content": "A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.Led by researchers at NYU Grossman School o\u2026 [+4486 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Soumya Eswaran",
            "title": "AbbVie (ABBV) Fell in Q2 Due to Competition",
            "description": "Diamond Hill Capital, an investment management company, released its \u201cLarge Cap Strategy\u201d second-quarter 2023 investor letter. A copy of the same can be...",
            "url": "https://finance.yahoo.com/news/abbvie-abbv-fell-q2-due-123220563.html",
            "urlToImage": "https://media.zenfs.com/en/insidermonkey.com/8577738f84a3c852cf540caf7ca4aba5",
            "publishedAt": "2023-09-15T12:32:20Z",
            "content": "Diamond Hill Capital, an investment management company, released its Large Cap Strategy second-quarter 2023 investor letter. A copy of the same can be\u00a0downloaded here. In the second quarter, the stra\u2026 [+2281 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Royal Society of Chemistry"
            },
            "author": "Yunhua Chen, Jiashan Mi, Aaron J. Rossini",
            "title": "A focus on detection of polymorphs by dynamic nuclear polarization solid-state nuclear magnetic resonance spectroscopy",
            "description": "Chem. Sci., 2023, Advance ArticleDOI: 10.1039/D3SC90177G, Commentary Open Access &nbsp This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Yunhua Chen, Jiashan Mi, Aaron J. RossiniCousin et al. (Chem. Sci., 2023, https://doi.org\u2026",
            "url": "https://pubs.rsc.org/en/content/articlelanding/2023/sc/d3sc90177g",
            "urlToImage": "https://pubs.rsc.org/en/Content/Image/GA/D3SC90177G",
            "publishedAt": "2023-09-27T23:00:00Z",
            "content": "* \r\n Corresponding authors\r\na\r\n Department of Chemistry, Iowa State University, Ames, IA 50011, USA\r\nE-mail:arossini@iastate.edu\r\nb\r\n Analytical Research &amp; Development, AbbVie, Inc., North Chicag\u2026 [+21 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Zacks.com"
            },
            "author": "247patrick",
            "title": "Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK\u2019s Drugs",
            "description": "Featured stocks include AbbVie and Johnson & Johnson.",
            "url": "https://www.zacks.com/stock/news/2157714/pharma-stock-roundup-fda-and-ema-regulatory-updates-for-abb",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg",
            "publishedAt": "2023-09-30T02:37:54Z",
            "content": "This week, the European Commission granted marketing approval to AbbVies ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lill\u2026 [+6152 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Zacks.com"
            },
            "author": "247patrick",
            "title": "The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J",
            "description": "Featured stocks include AbbVie and Johnson & Johnson.",
            "url": "https://www.zacks.com/stock/news/2158561/the-zacks-analyst-blog-highlights-abbvie-lilly-sanofi-merck",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2022/03/imageForEntry1-1b7.jpg",
            "publishedAt": "2023-10-03T02:45:31Z",
            "content": "Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks\u2026 [+6538 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Vardah Gill",
            "title": "15 Best S&P 500 Stocks For Dividend Growth",
            "description": "In this article, we discuss 15 best S&P 500 dividend stocks for dividend growth. You can skip our detailed analysis of dividend growth stocks and their...",
            "url": "https://finance.yahoo.com/news/15-best-p-500-stocks-211112359.html",
            "urlToImage": "https://media.zenfs.com/en/insidermonkey.com/f672f3ee560581084143c1645d9d38c2",
            "publishedAt": "2023-09-12T21:11:12Z",
            "content": "In this article, we discuss 15 best S&amp;P 500 dividend stocks for dividend growth. You can skip our detailed analysis of dividend growth stocks and their performance over the years, and go directly\u2026 [+12606 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "24/7 Wall St."
            },
            "author": "Lee Jackson",
            "title": "Monday\u2019s Top Analyst Upgrades and Downgrades: AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch, Bumble, Fortinet, Nike, Palo Alto Networks and More",
            "description": "Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.",
            "url": "https://247wallst.com/investing/2023/10/02/mondays-top-analyst-upgrades-and-downgrades-abbvie-adobe-advance-auto-parts-anheuser-busch-inbev-bumble-fortinet-nike-palo-alto-networks/",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2020/04/imageForEntry1-Qgh.jpg",
            "publishedAt": "2023-10-02T12:44:56Z",
            "content": "The futures were lower as we prepare to start a new week and the final quarter of 2023. The major indexes closed lower across the board on Friday, with the S&amp;P 500 closing down for the fourth str\u2026 [+3939 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Aima Zaheer",
            "title": "12 Best Pharma ETFs",
            "description": "In this article, we discuss the 12 best pharma ETFs. If you want to skip our discussion on the pharma industry, you can go directly to the 5 Best Pharma ETFs...",
            "url": "https://finance.yahoo.com/news/12-best-pharma-etfs-211618251.html",
            "urlToImage": "https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a",
            "publishedAt": "2023-09-12T21:16:18Z",
            "content": "In this article, we discuss the 12 best pharma ETFs. If you want to skip our discussion on the pharma industry, you can go directly to the 5 Best Pharma ETFs.\r\nAs of 2023, Deloitte has valued the pha\u2026 [+14889 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Plos.org"
            },
            "author": "Eva-Juliane Vollstedt, Harutyun Madoev, Anna Aasly, Azlina Ahmad-Annuar, Bashayer Al-Mubarak, Roy N. Alcalay, Victoria Alvarez, Ignacio Amorin, Grazia Annesi, David Arkadir, Soraya Bardien, Roger A. Barker, Melinda Barkhuizen, A. Nazli Basak, Vincenzo Bonifati, Agnita Boon, Laura Brighina, Kathrin Brockmann, Andrea Carmine Belin, Jonathan Carr, Jordi Clarimon, Mario Cornejo-Olivas, Leonor Correia Guedes, Jean-Christophe Corvol, David Crosiers, Joana Dam\u00e1sio, Parimal Das, Patricia de Carvalho Aguiar, Anna De Rosa, Jolanta Dorszewska, Sibel Ertan, Rosangela Ferese, Joaquim Ferreira, Emilia Gatto, Gen\u00e7er Gen\u00e7, Nir Giladi, Pilar G\u00f3mez-Garre, Hasmet Hanagasi, Nobutaka Hattori, Faycal Hentati, Dorota Hoffman-Zacharska, Sergey N. Illarioshkin, Joseph Jankovic, Silvia Jes\u00fas, Valtteri Kaasinen, Anneke Kievit, Peter Klivenyi, Vladimir Kostic, Dariusz Koziorowski, Andrea A. K\u00fchn, Anthony E. Lang, Shen-Yang Lim, Chin-Hsien Lin, Katja Lohmann, Vladana Markovic, Mika Henrik Martikainen, George Mellick, Marcelo Merello, Lukasz Milanowski, Pablo Mir, \u00d6zg\u00fcr \u00d6ztop-\u00c7akmak, M\u00e1rcia Mattos Gon\u00e7alves Pimentel, Teeratorn Pulkes, Andreas Puschmann, Ekaterina Rogaeva, Esther M. Sammler, Maria Skaalum Petersen, Matej Skorvanek, Mariana Spitz, Oksana Suchowersky, Ai Huey Tan, Pichet Termsarasab, Avner Thaler, Vitor Tumas, Enza Maria Valente, Bart van de Warrenburg, Caroline H. Williams-Gray, Ruey-Mei Wu, Baorong Zhang, Alexander Zimprich, Justin Solle, Shalini Padmanabhan, Christine Klein",
            "title": "Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson\u2019s Disease Project",
            "description": "Parkinson\u2019s disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk f\u2026",
            "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292180",
            "urlToImage": "https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292180.g003&size=inline",
            "publishedAt": "2023-10-03T14:00:00Z",
            "content": "Citation: Vollstedt E-J, Madoev H, Aasly A, Ahmad-Annuar A, Al-Mubarak B, Alcalay RN, et al. (2023) Establishing an online resource to facilitate global collaboration and inclusion of underrepresente\u2026 [+12141 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Vardah Gill",
            "title": "15 Worst Performing Dividend Stocks YTD",
            "description": "In this article, we discuss 15 worst performing dividend stocks year-to-date. You can skip our detailed analysis of dividend stocks and their performance...",
            "url": "https://finance.yahoo.com/news/15-worst-performing-dividend-stocks-001209139.html",
            "urlToImage": "https://media.zenfs.com/en/insidermonkey.com/8b188cbde663decbf2cf6049a11f9e0c",
            "publishedAt": "2023-09-14T00:12:09Z",
            "content": "In this article, we discuss 15 worst performing dividend stocks year-to-date. You can skip our detailed analysis of dividend stocks and their performance this year, and go directly to read 5 Worst Pe\u2026 [+12808 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Publicnow",
            "title": "AbbVie : Results of Operations and Financial Condition - Form 8-K",
            "description": "(marketscreener.com) \n \n \n \n AbbVie Inc.\n \n \n Guidance Including the Impact of Acquired IPR&D and Milestones Expense\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Quarter Ended September 30, 2023\n \n \n Full-Year...https://www.marketscreener.com/quote/stock/ABBVIE-INC-1213658\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Results-of-Operations-and-Financial-Condition-Form-8-K-44985403/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-04T20:14:05Z",
            "content": "Disclaimer\r\nAbbVie Inc. published this content on 04 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2023 20\u2026 [+10 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research Nester",
            "title": "IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester",
            "description": "Leading IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market players include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company (BMS), UCB, Inc., Biogen, Inc., Pfizer, Inc., Janssen Global Services, LLC, Takeda Pharm\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747129/0/en/IBD-Ulcerative-Colitis-and-Crohn-s-Disease-Treatment-Market-revenue-to-hit-USD-36-Billion-by-2033-says-Research-Nester.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/77e335b1-e272-4a4c-a0ff-211ce0caee29",
            "publishedAt": "2023-09-21T11:00:00Z",
            "content": "New York, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is estimated to grow at a CAGR of ~8% over the forecast period. The market is est\u2026 [+11321 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research Nester",
            "title": "Oncology Active Pharmaceutical Ingredient (API) Market revenue to reach USD 7 Billion by 2035, says Research Nester",
            "description": "Leading Oncology Active Pharmaceutical Ingredient (API) Market players include Sanofi, AbbVie Inc., Merck & Co. Inc., Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., GSK plc, Teva Pharmaceutical Industries Ltd. a\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/27/2750196/0/en/Oncology-Active-Pharmaceutical-Ingredient-API-Market-revenue-to-reach-USD-7-Billion-by-2035-says-Research-Nester.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/77e335b1-e272-4a4c-a0ff-211ce0caee29",
            "publishedAt": "2023-09-27T10:30:00Z",
            "content": "New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global oncology active pharmaceutical ingredient (API) Market size is expected to expand at ~ 7% CAGR from 2023 to 2035. The market is anticipated to \u2026 [+8401 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "AbbVie's blood cancer combo therapy fails in late-stage study",
            "description": "(marketscreener.com) AbbVie said on Friday its\nexperimental combination therapy to treat a form of blood cancer\ndid not meet the main goal in a late-stage study.\n \n https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-s-blood-cancer-comb\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-s-blood-cancer-combo-therapy-fails-in-late-stage-study-44952236/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-29T11:20:26Z",
            "content": "September 29, 2023 at 07:20 am EDT\r\nSept 29 (Reuters) - AbbVie said on Friday its\r\nexperimental combination therapy to treat a form of blood cancer\r\ndid not meet the main goal in a late-stage study.\r\u2026 [+70 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Harpoon Therapeutics Says AbbVie Declines to Exercise License Option",
            "description": "(marketscreener.com) \n By Ben Glickman \n\n\n Harpoon Therapeutics said on Wednesday that AbbVie won't exercise its exclusive license option on Harpoon's HPN217 program. \n\n The South San Francisco, Calif.-based immuno-oncology company said that AbbVie had the op\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Harpoon-Therapeutics-Says-AbbVie-Declines-to-Exercise-License-Option-44837396/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-13T20:41:02Z",
            "content": "By Ben Glickman \r\nHarpoon Therapeutics said on Wednesday that AbbVie won't exercise its exclusive license option on Harpoon's HPN217 program. \r\nThe South San Francisco, Calif.-based immuno-oncology c\u2026 [+493 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "AbbVie Exercises Right to Buy Biotech Mitokinin for Initial $110 Million",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n AbbVie has exercised its exclusive right to buy discovery-stage biotechnology company Mitokinin in a deal that bolsters the biopharmaceutical company's neuroscience pipeline. \n\n AbbVie on Thursday said it paid $110\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Exercises-Right-to-Buy-Biotech-Mitokinin-for-Initial-110-Million-44992500/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-05T12:39:03Z",
            "content": "By Colin Kellaher \r\nAbbVie has exercised its exclusive right to buy discovery-stage biotechnology company Mitokinin in a deal that bolsters the biopharmaceutical company's neuroscience pipeline. \r\nAb\u2026 [+817 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "AbbVie Advancing Rinvoq to Phase 3 Studies in Vitiligo",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n AbbVie on Thursday said it is moving its blockbuster immunology drug Rinvoq into Phase 3 studies in vitiligo after a successful Phase 2b study in the chronic skin condition. \n\n The North Chicago, Ill., biopharmaceu\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Advancing-Rinvoq-to-Phase-3-Studies-in-Vitiligo-45048538/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-12T10:15:02Z",
            "content": "By Colin Kellaher \r\nAbbVie on Thursday said it is moving its blockbuster immunology drug Rinvoq into Phase 3 studies in vitiligo after a successful Phase 2b study in the chronic skin condition. \r\nThe\u2026 [+1059 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n AbbVie on Friday said a Phase 3 study evaluating the safety and efficacy of its venetoclax cancer drug in combination with dexamethasone missed its key goal in certain patients with the blood cancer multiple myelom\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Phase-3-Venetoclax-Dexamethasone-Study-Falls-Short-in-Multiple-Myeloma-44952641/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-29T12:01:15Z",
            "content": "By Colin Kellaher \r\nAbbVie on Friday said a Phase 3 study evaluating the safety and efficacy of its venetoclax cancer drug in combination with dexamethasone missed its key goal in certain patients wi\u2026 [+1337 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma",
            "description": "(marketscreener.com) \n\nCANOVA study evaluated venetoclax plus dexamethasone in patients with t-positive multiple myeloma compared to pomalidomide plus dexamethasoneResults are being presented at the International Myeloma Society Annual Meeting in Athens, Gree\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Presents-Results-from-Phase-3-CANOVA-Study-of-Venetoclax-in-Patients-with-Relapsed-or-Refract-44952149/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-29T11:16:03Z",
            "content": "<ul><li>CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone</li><li>Results are being presented at the\u2026 [+17901 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Harpoon Shares Drop 7.3% as AbbVie Declines License Option",
            "description": "(marketscreener.com) \n By Ben Glickman \n\n\n Shares of Harpoon Therapeutics fell Wednesday after the company said AbbVie wouldn't exercise an exclusive license option on one of its treatments. \n\n The stock was down 7.3% to $6.06 after-hours, after falling 4% at\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Harpoon-Shares-Drop-7-3-as-AbbVie-Declines-License-Option-44837562/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-13T20:58:02Z",
            "content": "By Ben Glickman \r\nShares of Harpoon Therapeutics fell Wednesday after the company said AbbVie wouldn't exercise an exclusive license option on one of its treatments. \r\nThe stock was down 7.3% to $6.0\u2026 [+497 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline",
            "description": "(marketscreener.com) \n\n-\u00a0 Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease\n-\u00a0 Activation of PINK1 remediates mitochondrial damage and re\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Exercises-Exclusive-Right-to-Acquire-Mitokinin-Further-Strengthening-Neuroscience-Pipeline-44992009/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-05T12:06:03Z",
            "content": "-\u00a0 Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease\r\n-\u00a0 Activation of PINK1 \u2026 [+5205 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Ramish Cheema",
            "title": "12 Best Mid-Cap Value ETFs",
            "description": "In this piece, we will take a look at the 12 best mid-cap value ETFs. If you want to skip our primer on value and mid-cap investing as well as the latest...",
            "url": "https://finance.yahoo.com/news/12-best-mid-cap-value-205957154.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/kUwkPd1Zu3lQENUUSOnbPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/a7f5303b30734f06006e3345a542a451",
            "publishedAt": "2023-09-14T20:59:57Z",
            "content": "In this piece, we will take a look at the 12 best mid-cap value ETFs. If you want to skip our primer on value and mid-cap investing as well as the latest trends in the stock market, then check out 5 \u2026 [+9754 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investing.com"
            },
            "author": "Investing.com",
            "title": "Several layers to set up long-term growth for AbbVie - Raymond James",
            "description": "Several layers to set up long-term growth for AbbVie - Raymond James",
            "url": "https://www.investing.com/news/stock-market-news/several-layers-to-set-up-longterm-growth-for-abbvie--raymond-james-432SI-3186583",
            "urlToImage": "https://i-invdn-com.investing.com/news/moved_LYNXMPEH9S0OB_L.jpg",
            "publishedAt": "2023-09-29T16:07:07Z",
            "content": "Raymond James initiated coverage of AbbVie Inc (NYSE:ABBV) with an Outperform rating and $177 price target in a note Friday.\r\nAnalysts told investors that looking beyond Humira, there are several lay\u2026 [+1062 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy",
            "description": "(marketscreener.com) \n\nNORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/ -- AbbVie , the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature\u00a0of the discovery and preclinical data \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Nature-Publishes-Discovery-and-Preclinical-Results-for-ABBV-CLS-484-a-Potential-First-in-Class-PTPN-44983645/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-04T15:08:03Z",
            "content": "NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication\u2026 [+6926 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023",
            "description": "(marketscreener.com) \n\n\u2013\u00a0 \u00a0Late-breaking data from a head-to-head study evaluating SKYRIZI\u00ae \u00a0versus STELARA\u00ae in moderate to severe Crohn's disease will be presented\u2013 \u00a0 Analyses on clinical and endoscopic outcomes from AbbVie's maintenance trials for SKYRIZI\u00ae \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Showcases-Breadth-and-Depth-of-Research-in-Crohn-s-Disease-and-Ulcerative-Colitis-at-UEG-Week-45029291/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-10T12:46:04Z",
            "content": "Late-breaking data from a head-to-head study evaluating SKYRIZI\u00ae (risankizumab)\u00a0versus STELARA\u00ae (ustekinumab) in moderate to severe Crohn's disease will be presented \u00a0 Analyses on clinical and endosc\u2026 [+31564 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "AbbVie's SKYRIZI\u00ae (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara\u00ae (ustekinumab) in Head-to-Head Study in Crohn's Disease",
            "description": "(marketscreener.com) \n\nSEQUENCE, a Phase 3 head-to-head study compared\u00a0risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1Risankizumab met both primary endpo\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-s-SKYRIZI-risankizumab-Met-All-Primary-and-Secondary-Endpoints-Versus-Stelara-ustekinuma-44823568/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-12T12:31:08Z",
            "content": "<ul><li>SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared\u00a0risankizumab to ustekinumab for the treatment of adult patients with moderately to seve\u2026 [+15436 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging process that disrupts the neck, jawline and lower face. \n\n AbbVie's Allergan unit \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-s-Botox-Meets-Key-Goals-in-2nd-Platysma-Prominence-Study-44867632/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-18T13:45:02Z",
            "content": "By Colin Kellaher \r\nA second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging process that disrupts the neck, jawline and low\u2026 [+977 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "AbbVie Announces European Commission Approval of TEPKINLY\u00ae (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "description": "(marketscreener.com) \n\nTEPKINLY\u00ae is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapyConditional marketing aut\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Announces-European-Commission-Approval-of-TEPKINLY-epcoritamab-for-Adults-with-Relapsed-or-44914480/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-25T11:46:03Z",
            "content": "<ul><li>TEPKINLY\u00ae (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two\u2026 [+21968 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "CMI MARKET RESEARCH PRIVATE LIMITED",
            "title": "[Latest] Global Antibacterial Drugs Market Size/Share Worth USD 67.9 Billion by 2032 at a 5.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)",
            "description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Antibacterial Drugs Market size & share revenue was valued at approximately USD 51.55 Billion in 2022 and is expected to reach U\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2749024/0/en/Latest-Global-Antibacterial-Drugs-Market-Size-Share-Worth-USD-67-9-Billion-by-2032-at-a-5-6-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/74609d89-5437-4826-b7b8-31238ea2e65c",
            "publishedAt": "2023-09-25T21:00:00Z",
            "content": "Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled Antibacterial Drugs Market Size, Trends and Insights By Drug Class (Cephalosporin\u2026 [+23615 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "marketbeat.com",
            "title": "Flee to Healthcare Stocks if Recession Rears its Head?",
            "description": "If you\u2019re looking for a sector that\u2019s on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500. The top components within the sector are Eli Lilly & Co. NYSE: LLY, Johnson & Johnso\u2026",
            "url": "https://biztoc.com/x/d8c4de74bb2564b6",
            "urlToImage": "https://c.biztoc.com/p/d8c4de74bb2564b6/s.webp",
            "publishedAt": "2023-09-20T11:06:38Z",
            "content": "If youre looking for a sector thats on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&amp;P 500.The top components with\u2026 [+309 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis",
            "description": "(marketscreener.com) \n\nThree ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ\u00ae in treating moderate to severe atopic dermatitis based on results across 140 weeks1 Response rates fo\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Presents-Long-Term-Data-Further-Supporting-the-Efficacy-and-Safety-Profile-of-RINVOQ-upadaci-45039889/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-11T12:31:09Z",
            "content": "<ul><li>Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ\u00ae (upadacitinib) in treating moderate to severe atopic der\u2026 [+25156 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Zion Market Research",
            "title": "Transforming Skin Care: Atopic Eczema Treatment Market Size Predicted to Flourish to USD 13 Billion by 2030, with a 7.14% CAGR",
            "description": "[219 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global Atopic Eczema Treatment Market size & share revenue was valued at around USD 10 billion in 2022 and is estimated to grow about USD 13 bi\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/22/2747943/0/en/Transforming-Skin-Care-Atopic-Eczema-Treatment-Market-Size-Predicted-to-Flourish-to-USD-13-Billion-by-2030-with-a-7-14-CAGR.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/1f4cf0ab-7d76-4136-a6dc-a5545f80f538",
            "publishedAt": "2023-09-22T12:02:00Z",
            "content": "New York, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled Atopic Eczema Treatment Market - By Drug Class (Biologics And PDE4 Inhibitors), By Rou\u2026 [+15804 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Zacks.com"
            },
            "author": "247patrick",
            "title": "The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca",
            "description": "Featured stocks include pharmaceutical giants Merck and Pfizer.",
            "url": "https://www.zacks.com/stock/news/2154894/the-zacks-analyst-blog-highlights-pfizer-merck-and-astrazen",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2018/06/gettyimages-72561161-e1530130096567.jpg",
            "publishedAt": "2023-09-26T02:42:20Z",
            "content": "Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks\u2026 [+4706 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Harpoon Therapeutics Inc.",
            "title": "Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie",
            "description": "SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercis\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742865/0/en/Harpoon-Therapeutics-Provides-an-Update-on-the-HPN217-Development-and-Option-Agreement-with-AbbVie.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/7e618bf2-6d57-40b3-bdd8-00765a1ed497",
            "publishedAt": "2023-09-13T20:05:00Z",
            "content": "SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today t\u2026 [+4763 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX\u00ae Cosmetic) for the Treatment of Platysma Prominence",
            "description": "(marketscreener.com) \n\n\u2013All primary and secondary endpoints were met for second Phase 3 study and results were consistent with findings from first Phase 3 study .\u2013Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platys\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Allergan-Aesthetics-Announces-Positive-Topline-Results-from-Second-Phase-3-Study-of-Onabotulinumtoxi-44867233/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-18T13:01:11Z",
            "content": "All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).Results support onabotulinumtoxinA as a po\u2026 [+15862 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Ankylosing Spondylitis Market is Projected to Reach $7.29 Billion by 2027: Leading Players Pfizer, AbbVie, and Novartis Drive Advances in Treatment Options",
            "description": "Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The \"Ankylosing Spondylitis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/10/12/2759110/28124/en/Global-Ankylosing-Spondylitis-Market-is-Projected-to-Reach-7-29-Billion-by-2027-Leading-Players-Pfizer-AbbVie-and-Novartis-Drive-Advances-in-Treatment-Options.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-12T11:03:00Z",
            "content": "Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The \"Ankylosing Spondylitis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global ankylosing spondylitis market \u2026 [+9728 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Presbyopia Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies - Eyenovia, Orasis, Ocuphire Pharma, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, AbbVie",
            "description": "The presbyopia market is predicted to grow during the forecast period (2023\u20132032) owing to the development of well-designed, randomized trials to study novel drugs with potential benefits for Presbyopia patients, the shortfall of approved therapy, and the lau\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/14/2743582/0/en/Presbyopia-Market-to-Exhibit-Significant-Growth-by-2032-Predicts-DelveInsight-Key-Companies-Eyenovia-Orasis-Ocuphire-Pharma-Visus-Therapeutics-LENZ-Therapeutics-Glaukos-Corporation.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-09-14T17:00:00Z",
            "content": "New York, USA, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Presbyopia Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies - Eyenovia, Orasis, Ocuphire Pharma, Visus Therapeutic\u2026 [+17283 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Active Pharmaceutical Ingredients (API) Market Expected to Reach USD 284.4 Billion by 2027 At a 6.4% CAGR by 2027 | Brandessence Market Research",
            "description": "LONDON , Sept. 26, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), \"Active Pharmaceutical Ingredients (API) Market Industry Analysis, Trends, And Forecast 2020-2027\". The Active Pharmaceutical Ingredie\u2026",
            "url": "https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-api-market-expected-to-reach-usd-284-4-billion-by-2027-at-a-6-4-cagr-by-2027--brandessence-market-research-301938480.html",
            "urlToImage": "https://mma.prnewswire.com/media/1392316/4254672/BEMR_Logo.jpg?p=facebook",
            "publishedAt": "2023-09-26T07:13:00Z",
            "content": "LONDON\u00a0, Sept. 26, 2023 /PRNewswire/ -- According to a comprehensive research report by\u00a0Brandessence Market Research (BMRC), \"Active Pharmaceutical Ingredients (API) Market Industry Analysis, Trends,\u2026 [+11057 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",
            "description": "The Growth of the small-cell lung cancer market is expected to be driven by increasing incident cases of SCLC, mainly due to an increase in the geriatric population, the expected entry of potential premium price emerging therapies, and the expected readily up\u2026",
            "url": "https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-10-04T21:01:00Z",
            "content": "The Growth of the small-cell lung cancer market is expected to be driven by increasing incident cases of SCLC, mainly due to an increase in the geriatric population, the expected entry of potential p\u2026 [+16072 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PR Newswire UK"
            },
            "author": null,
            "title": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",
            "description": "The Growth of the small-cell lung cancer market is expected to be driven by increasing incident cases of SCLC, mainly due to an increase in the geriatric population, the expected entry of potential premium price emerging therapies, and the expected readily up\u2026",
            "url": "https://www.prnewswire.co.uk/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946618.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-10-04T21:01:00Z",
            "content": "The Growth of the small-cell lung cancer market is expected to be driven by increasing incident cases of SCLC, mainly due to an increase in the geriatric population, the expected entry of potential p\u2026 [+16077 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Rising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment Market",
            "description": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Optic Nerves Disorder Treatment Market by Treatment Type, Indication, Distribution Channel, and Geography: Forecast up to 2027\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748610/28124/en/Rising-Glaucoma-Cases-Forecast-a-Strong-Optic-Nerves-Disorder-Treatment-Market.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-25T12:08:00Z",
            "content": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Optic Nerves Disorder Treatment Market by Treatment Type, Indication, Distribution Channel, and Geography: Forecast up to 2027\" report has been added t\u2026 [+2896 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ValueWalk"
            },
            "author": "Anna Peel",
            "title": "The Fortune 500 Companies Earning The Most (And Least) Profit Per Worker",
            "description": "At the Australian Financial Review Property Summit, multi-millionaire CEO Tim Gurner sparked global backlash after saying that \u201cunemployment has to ... Read more",
            "url": "https://www.valuewalk.com/the-fortune-500-companies-earning-the-most-and-least-profit-per-worker/",
            "urlToImage": "https://www.valuewalk.com/wp-content/uploads/2022/12/3-simple-things-you-can-do-today-to-improve-your-finances.jpeg",
            "publishedAt": "2023-09-14T17:25:51Z",
            "content": "<ul><li>Out of the Fortune 500, eight oil companies have the highest profits per worker, with Diamondback Energy earning an eye-watering $4.5 million per employee</li><li>Of the Fortune 100 minus oil\u2026 [+7094 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Partnerships Drive Innovation in the Leukemia Therapeutics Market: Pfizer Leads with Approval for DAURISMO, Enabling Novel Treatment Possibilities",
            "description": "Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The \"Global Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Regional Outlook and Fore\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/22/2747795/28124/en/Partnerships-Drive-Innovation-in-the-Leukemia-Therapeutics-Market-Pfizer-Leads-with-Approval-for-DAURISMO-Enabling-Novel-Treatment-Possibilities.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-22T08:28:00Z",
            "content": "Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The \"Global Leukemia Therapeutics Market Size, Share &amp; Industry Trends Analysis Report By Drug Class (Targeted Therapy &amp; Immunotherapy and Chemother\u2026 [+4891 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda",
            "description": "The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the third-line setting, whereas uptake of CD-19 targeted CART-Ts and CD79b targeted ADC is expected in the e\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/19/2745941/0/en/Diffuse-Large-B-cell-Lymphoma-Market-to-Show-Immense-Growth-by-2032-Predicts-DelveInsight-Leading-Players-to-Look-Out-AbbVie-Genmab-Merck-Xencor-Janssen-Roche-Biogen-Regeneron-Seag.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-09-19T17:00:00Z",
            "content": "New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xen\u2026 [+19636 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Aesthetic Lasers and Energy Devices Market to grow by USD 1.91 billion between 2022 - 2027, Growth Driven by the Growing Geriatric Population - Technavio",
            "description": "NEW YORK, Sept. 19, 2023 /PRNewswire/ -- The Aesthetic Lasers And Energy Devices Market report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio has proudly partnered with more than 100 Fortune 500 companies for over 16 years\u2026",
            "url": "https://www.prnewswire.com/news-releases/aesthetic-lasers-and-energy-devices-market-to-grow-by-usd-1-91-billion-between-2022---2027--growth-driven-by-the-growing-geriatric-population---technavio-301930534.html",
            "urlToImage": "https://mma.prnewswire.com/media/2213413/20230727100444_bw_2023_v1.jpg?p=facebook",
            "publishedAt": "2023-09-19T15:15:00Z",
            "content": "NEW YORK, Sept. 19, 2023 /PRNewswire/ -- The Aesthetic Lasers And Energy Devices Market\u00a0report has been added to Technavio's offering.\u00a0With ISO 9001:2015 certification, Technavio has proudly partnere\u2026 [+6948 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Acumen Research and Consulting",
            "title": "Myasthenia Gravis Treatment Market is forecasted to reach USD 2.6 Billion by 2032, growing at a 7.3% CAGR from 2023 to 2032",
            "description": "Acumen Research and Consulting recently published report titled \u201cMyasthenia Gravis Treatment Market Forecast, 2023 - 2032\u201d Acumen Research and Consulting recently published report titled \u201cMyasthenia Gravis Treatment Market Forecast, 2023 - 2032\u201d",
            "url": "https://www.globenewswire.com/news-release/2023/10/03/2753922/0/en/Myasthenia-Gravis-Treatment-Market-is-forecasted-to-reach-USD-2-6-Billion-by-2032-growing-at-a-7-3-CAGR-from-2023-to-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d",
            "publishedAt": "2023-10-03T15:12:00Z",
            "content": "LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The Global Myasthenia Gravis Treatment Market Size accounted for USD 1.3 Billion in 2022 and is projected to achieve a market size of USD 2.6 Billion by\u2026 [+9049 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Fortune Business Insights",
            "title": "Psoriasis Treatment Market Size to Surpass USD 51.48 Billion by 2030, at a CAGR of 8.8%",
            "description": "As per the report by Fortune Business Insights, The global psoriasis treatment market size was valued at USD 26.37 billion in 2022 and is expected to be worth USD 28.61 billion in 2023. The market is projected to reach USD 51.48 billion by 2030, recording a C\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/09/2756764/0/en/Psoriasis-Treatment-Market-Size-to-Surpass-USD-51-48-Billion-by-2030-at-a-CAGR-of-8-8.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/05408ba1-26b1-4fdd-8f48-1af4df373348",
            "publishedAt": "2023-10-09T13:17:00Z",
            "content": "Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The global psoriasis treatment market\r\n size was valued at USD 26.37 billion in 2022 and market is projected to reach USD 51.48 billion by 2030 recordin\u2026 [+12046 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Biologics and Personalized Medicine to Fuel Growth in the Plaque Psoriasis Treatment Market, With Telemedicine and Digital Health Playing a Role",
            "description": "Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The \"Global Plaque Psoriasis Treatment Market Report and Forecast 2023-2031\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/22/2747980/28124/en/Biologics-and-Personalized-Medicine-to-Fuel-Growth-in-the-Plaque-Psoriasis-Treatment-Market-With-Telemedicine-and-Digital-Health-Playing-a-Role.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-22T12:43:00Z",
            "content": "Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The \"Global Plaque Psoriasis Treatment Market Report and Forecast 2023-2031\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global plaque \u2026 [+3992 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Acumen Research and Consulting",
            "title": "Organ Transplant Rejection Medication Market Size Estimated to Reach USD 7.4 Billion by 2032, Growing at a CAGR of 3.4%",
            "description": "Acumen Research and Consulting recently published report titled \u201cOrgan Transplant Rejection Medication Market Forecast, 2023 - 2032\u201d Acumen Research and Consulting recently published report titled \u201cOrgan Transplant Rejection Medication Market Forecast, 2023 -\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748840/0/en/Organ-Transplant-Rejection-Medication-Market-Size-Estimated-to-Reach-USD-7-4-Billion-by-2032-Growing-at-a-CAGR-of-3-4.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d",
            "publishedAt": "2023-09-25T15:00:00Z",
            "content": "LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The Organ Transplant Rejection Medication Market is poised for steady growth globally, although side effects remain a key concern, driven by rise in tr\u2026 [+9648 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "GlobeNewswire",
            "title": "IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors",
            "description": "(marketscreener.com) MOUNTAIN VIEW, Calif., Oct. 03, 2023 -- IGM Biosciences, Inc. , a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of \u2026",
            "url": "https://www.marketscreener.com/quote/stock/IGM-BIOSCIENCES-INC-65338650/news/IGM-Biosciences-Announces-Retirement-of-Chairman-Michael-Loberg-Ph-D-from-Board-of-Directors-and-A-44975699/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-03T20:06:07Z",
            "content": "MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod\u2026 [+4332 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Addressing Unmet Needs: The SLE Market Grows as Research and Development Flourish",
            "description": "Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The \"Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)\" report has been added to Researc\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/06/2755972/28124/en/Addressing-Unmet-Needs-The-SLE-Market-Grows-as-Research-and-Development-Flourish.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-06T10:08:00Z",
            "content": "Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The \"Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, &amp; Region): Insights &amp; Forecast with Potent\u2026 [+3601 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "MarketsandMarkets Research Pvt. Ltd.",
            "title": "Precision Medicine Market is Expected to Reach $50.2 billion | MarketsandMarkets.",
            "description": "Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid advancements in technology, changing healthcare delivery models, and evolving educational methodologies. Wit\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/12/2741656/0/en/Precision-Medicine-Market-is-Expected-to-Reach-50-2-billion-MarketsandMarkets.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/afcc5182-4ae0-43a8-a965-4351d590b7ed",
            "publishedAt": "2023-09-12T12:30:00Z",
            "content": "Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid advancements in technology, changing healthcare \u2026 [+9810 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Acumen Research and Consulting",
            "title": "Pruritus Therapeutics Market Size Comprehensive Outlook Predicts a 3.9% CAGR, Achieving a Valuation of USD 12.1 Billion by 2032",
            "description": "Acumen Research and Consulting recently published report titled \u201cPruritus Therapeutics Market Forecast, 2023 - 2032\u201d Acumen Research and Consulting recently published report titled \u201cPruritus Therapeutics Market Forecast, 2023 - 2032\u201d",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747410/0/en/Pruritus-Therapeutics-Market-Size-Comprehensive-Outlook-Predicts-a-3-9-CAGR-Achieving-a-Valuation-of-USD-12-1-Billion-by-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d",
            "publishedAt": "2023-09-21T14:00:00Z",
            "content": "LOS ANGELES, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The Global Pruritus Therapeutics Market Size accounted for USD 8.4 Billion in 2022 and is projected to achieve a market size of USD 12.1 Billion by 203\u2026 [+8322 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Acumen Research and Consulting",
            "title": "Ankylosing Spondylitis Market Size Positioned for a Projected CAGR of 6.5% to Achieve a Valuation of USD 9.5 Billion by 2032",
            "description": "Acumen Research and Consulting recently published report titled \u201cAnkylosing Spondylitis Market Forecast, 2023 - 2032\u201d Acumen Research and Consulting recently published report titled \u201cAnkylosing Spondylitis Market Forecast, 2023 - 2032\u201d",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742669/0/en/Ankylosing-Spondylitis-Market-Size-Positioned-for-a-Projected-CAGR-of-6-5-to-Achieve-a-Valuation-of-USD-9-5-Billion-by-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d",
            "publishedAt": "2023-09-13T14:46:00Z",
            "content": "LOS ANGELES, Sept. 13, 2023 (GLOBE NEWSWIRE) -- \u00a0The Global Ankylosing Spondylitis Market Size accounted for USD 5.1 Billion in 2022 and is projected to achieve a market size of USD 9.5 Billion by 20\u2026 [+10055 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Enzyme Replacement Therapy (ERT) Market Research Report 2023: A $14.79 Million Market in 2027 at a CAGR of 8.1% - Long-term Forecast to 2032",
            "description": "Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The \"Enzyme Replacement Therapy Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.The global enzyme replacement therapy market is expected to grow from $10.03 billion in 2022 to $10\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/02/2752540/28124/en/Global-Enzyme-Replacement-Therapy-ERT-Market-Research-Report-2023-A-14-79-Million-Market-in-2027-at-a-CAGR-of-8-1-Long-term-Forecast-to-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-02T09:14:00Z",
            "content": "Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The \"Enzyme Replacement Therapy Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global enzyme replacement therapy\u2026 [+6083 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Persistence Market Research",
            "title": "Global Biologics Contract Manufacturing Demand to Surge to USD 42.01 billion by 2033, Fueling Innovative Therapies! Persistence Market Research",
            "description": "Biologics Contract Manufacturing Demand Market Segmented By Monoclonal Antibodies, Vaccines, Growth Factors, Interferons, Recombinant Hormones, Insulin Product with Mammalian, Microbial Platform Biologics Contract Manufacturing Demand Market Segmented By Mono\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/18/2745042/0/en/Global-Biologics-Contract-Manufacturing-Demand-to-Surge-to-USD-42-01-billion-by-2033-Fueling-Innovative-Therapies-Persistence-Market-Research.html",
            "urlToImage": null,
            "publishedAt": "2023-09-18T15:45:00Z",
            "content": "New York, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The global biologics contract manufacturing (CMO) demand market\r\n is expected to grow from USD 14.04 billion in 2022 to USD 42.01 billion by 2033, at a co\u2026 [+7975 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "MarketsandMarkets Research Pvt. Ltd.",
            "title": "Biotechnology Contract Manufacturing Market is Expected to Reach $24.8 billion | MarketsandMarkets.",
            "description": "Chicago, Sept. 22, 2023 (GLOBE NEWSWIRE) -- In the near future, the biotechnology contract manufacturing industry is poised to undergo a transformative evolution, fueled by rapid advances in genetic engineering, personalized medicine, and pharmaceutical innov\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/22/2747960/0/en/Biotechnology-Contract-Manufacturing-Market-is-Expected-to-Reach-24-8-billion-MarketsandMarkets.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/afcc5182-4ae0-43a8-a965-4351d590b7ed",
            "publishedAt": "2023-09-22T12:30:00Z",
            "content": "Chicago, Sept. 22, 2023 (GLOBE NEWSWIRE) -- In the near future, the biotechnology contract manufacturing industry is poised to undergo a transformative evolution, fueled by rapid advances in genetic \u2026 [+10955 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Immune Thrombocytopenia Market Set to Reach USD 3.39 Billion by 2031: Key Trends and Advancements",
            "description": "Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The \"Global Immune Thrombocytopenia Market Report and Forecast 2023-2031\" report has been added to ResearchAndMarkets.com's offering.The global immune thrombocytopenia market value was USD 3.12 billion in 2022, driven\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/10/2757192/28124/en/Immune-Thrombocytopenia-Market-Set-to-Reach-USD-3-39-Billion-by-2031-Key-Trends-and-Advancements.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-10T08:28:00Z",
            "content": "Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The \"Global Immune Thrombocytopenia Market Report and Forecast 2023-2031\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global immune thro\u2026 [+6171 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Progestin Options Set to Dominate Contraceptive Pills Market: Insights from 2023 to 2030",
            "description": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Global Contraceptive Pills Market by Hormone Type (Combination Pills, Progestin Pills), Category (Branded, Generic) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-20\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748526/28124/en/Progestin-Options-Set-to-Dominate-Contraceptive-Pills-Market-Insights-from-2023-to-2030.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-25T11:28:00Z",
            "content": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Global Contraceptive Pills Market by Hormone Type (Combination Pills, Progestin Pills), Category (Branded, Generic) - Cumulative Impact of COVID-19, Ru\u2026 [+4694 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Graft Versus Host Disease Treatment Market 2023-2030: Monoclonal Antibodies Lead Surge in Graft Versus Host Disease Treatment Market, Monitored by Comprehensive Vendor Analysis",
            "description": "Dublin, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The \"Global Graft Versus Host Disease Treatment Market by Disease Type, Product, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030\" report has been added to Re\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/13/2742310/28124/en/Global-Graft-Versus-Host-Disease-Treatment-Market-2023-2030-Monoclonal-Antibodies-Lead-Surge-in-Graft-Versus-Host-Disease-Treatment-Market-Monitored-by-Comprehensive-Vendor-Analysi.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-13T10:54:00Z",
            "content": "Dublin, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The \"Global Graft Versus Host Disease Treatment Market by Disease Type, Product, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High\u2026 [+5524 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Rationalstat LLC",
            "title": "Atopic Dermatitis Market 2023 \u2013 Uncovering Global Dynamics, Geographical Segmentation, and Forecast 2023-2030",
            "description": "The global atopic dermatitis market is expected to touch US$ 19.1 billion by 2030, with an annual growth rate of more than 8.7% The global atopic dermatitis market is expected to touch US$ 19.1 billion by 2030, with an annual growth rate of more than 8.7%",
            "url": "https://www.globenewswire.com/news-release/2023/10/12/2759225/0/en/Atopic-Dermatitis-Market-2023-Uncovering-Global-Dynamics-Geographical-Segmentation-and-Forecast-2023-2030.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/ced67b94-5d6b-4532-b365-e1f1f26f8f16",
            "publishedAt": "2023-10-12T12:15:00Z",
            "content": "Wilmington, Delaware, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Global \r\nAtopic Dermatitis\r\n Market\r\n value is estimated at US$ 10.7 billion in 2023 and is expected to grow at a significant CAGR of over 8.7%\u2026 [+10007 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Pharmaceutical Gelatin Market Set for Remarkable Growth, Projected Valuation of $2.17 Billion by 2032",
            "description": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's offerin\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748708/28124/en/Global-Pharmaceutical-Gelatin-Market-Set-for-Remarkable-Growth-Projected-Valuation-of-2-17-Billion-by-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-25T13:18:00Z",
            "content": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-203\u2026 [+5639 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Collaborative R&D Efforts and Rising Healthcare Investments Offer Lucrative Opportunities in the Global Genitourinary Drugs Market",
            "description": "Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The \"Global Genitourinary Drugs Market by Product, Indication, Drug Type - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030\" report has been added to ResearchAndMarkets.\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/19/2745627/28124/en/Collaborative-R-D-Efforts-and-Rising-Healthcare-Investments-Offer-Lucrative-Opportunities-in-the-Global-Genitourinary-Drugs-Market.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-19T12:33:00Z",
            "content": "Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The \"Global Genitourinary Drugs Market by Product, Indication, Drug Type - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Fore\u2026 [+5450 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Antibodies Industry Poised for Remarkable Growth as Therapeutic Applications Expand Worldwide",
            "description": "Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The \"Antibodies Market, By Drug Type, by Disease Indication By End User, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/15/2744056/28124/en/Antibodies-Industry-Poised-for-Remarkable-Growth-as-Therapeutic-Applications-Expand-Worldwide.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-15T13:43:00Z",
            "content": "Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The \"Antibodies Market, By Drug Type, by Disease Indication By End User, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030\" report\u2026 [+4420 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future",
            "description": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The \"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's offering. T\u2026",
            "url": "https://www.prnewswire.com/news-releases/innovative-gelatin-capsules-transforming-pharmaceutical-industry-a-look-into-the-future-301936082.html",
            "urlToImage": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "publishedAt": "2023-09-22T21:45:00Z",
            "content": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The\u00a0\"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032\" r\u2026 [+5562 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Viral Gastroenteritis Global Market Report 2023: A $7.68 Billion Market by 2027 - Product Innovation and FDA Approvals Fuel Growth to 2032",
            "description": "Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The \"Viral Gastroenteritis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.The global viral gastroenteritis market is expected to grow from $5.99 billion in 2022 to $6.34 billion \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/10/2757344/28124/en/Viral-Gastroenteritis-Global-Market-Report-2023-A-7-68-Billion-Market-by-2027-Product-Innovation-and-FDA-Approvals-Fuel-Growth-to-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-10T11:18:00Z",
            "content": "Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The \"Viral Gastroenteritis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global viral gastroenteritis market is\u2026 [+7040 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "IGM Biosciences, Inc.",
            "title": "IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors",
            "description": "MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/03/2754164/0/en/IGM-Biosciences-Announces-Retirement-of-Chairman-Michael-Loberg-Ph-D-from-Board-of-Directors-and-Appointment-of-Elizabeth-H-Z-Thompson-Ph-D-to-Board-of-Directors.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/312125d7-48ef-48f1-aa8e-a7532c2f21e8",
            "publishedAt": "2023-10-03T20:05:00Z",
            "content": "MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod\u2026 [+4332 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Elderly Population and Advancements in Biologics Fuel Demand for Dermatology Drugs Worldwide",
            "description": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2023-2032\" report has\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748704/28124/en/Elderly-Population-and-Advancements-in-Biologics-Fuel-Demand-for-Dermatology-Drugs-Worldwide.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-25T13:13:00Z",
            "content": "Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The \"Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution\u2026 [+5813 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities",
            "description": "Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The \"Ulcerative Colitis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/20/2746193/28124/en/Ulcerative-Colitis-Market-Soars-to-6-84-Billion-in-2023-Registering-a-7-7-CAGR-Unlocking-Lucrative-Investment-Opportunities.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-20T08:43:00Z",
            "content": "Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The \"Ulcerative Colitis Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global ulcerative colitis market is set \u2026 [+7025 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Rising Alcohol and Tobacco Consumption Linked to Aortic Aneurysms: Global Market Witnesses a Surge, Bolstered by Increased Health Risks",
            "description": "Dublin, Sept.  19, 2023  (GLOBE NEWSWIRE) -- The \"Aortic Aneurysm Global Market Report 2023\" report has been added to  ResearchAndMarkets.com's offering. ...",
            "url": "https://www.globenewswire.com/news-release/2023/09/19/2745361/28124/en/Rising-Alcohol-and-Tobacco-Consumption-Linked-to-Aortic-Aneurysms-Global-Market-Witnesses-a-Surge-Bolstered-by-Increased-Health-Risks.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-19T08:58:00Z",
            "content": "Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The \"Aortic Aneurysm Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global aortic aneurysm market is poised for\u2026 [+6166 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Projected Market Value: mTOR Inhibitors Market Set to Reach $8.76 Billion by 2027 with Novartis and Pfizer in the Lead",
            "description": "Dublin, Sept.  20, 2023  (GLOBE NEWSWIRE) -- The \"mTOR Inhibitors Global Market Report 2023\" report has been added to  ResearchAndMarkets.com's offering. ...",
            "url": "https://www.globenewswire.com/news-release/2023/09/20/2746187/28124/en/Projected-Market-Value-mTOR-Inhibitors-Market-Set-to-Reach-8-76-Billion-by-2027-with-Novartis-and-Pfizer-in-the-Lead.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-20T08:38:00Z",
            "content": "Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The \"mTOR Inhibitors Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global mTOR inhibitors market is on a stead\u2026 [+7642 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Challenges and Opportunities: Navigating the Injectable Drug Delivery Devices Market 2023",
            "description": "Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The \"Injectable Drug Delivery Devices Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747239/28124/en/Challenges-and-Opportunities-Navigating-the-Injectable-Drug-Delivery-Devices-Market-2023.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-21T12:08:00Z",
            "content": "Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The \"Injectable Drug Delivery Devices Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global injectable drug del\u2026 [+5311 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Charcot-Marie-Tooth Disease Market Size and Share to Grow by 2032, Predicts DelveInsight | Key Players in the Market - Pharnext, MedDay, HELIXMITH, ENCell, InFlectis, Addex, Augustine, DTx Pharma",
            "description": "The increase in the Charcot-Marie-Tooth disease market size is a direct consequence of increasing prevalent population of Charcot-Marie-Tooth disease patients in the 7MM. The increase in the Charcot-Marie-Tooth disease market size is a direct consequence of i\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/18/2745135/0/en/Charcot-Marie-Tooth-Disease-Market-Size-and-Share-to-Grow-by-2032-Predicts-DelveInsight-Key-Players-in-the-Market-Pharnext-MedDay-HELIXMITH-ENCell-InFlectis-Addex-Augustine-DTx-Pha.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-09-18T17:00:00Z",
            "content": "New York, USA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Charcot-Marie-Tooth Disease Market Size and Share to Grow by 2032, Predicts DelveInsight | Key Players in the Market - Pharnext, MedDay, HELIXMITH, E\u2026 [+17202 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Acumen Research and Consulting",
            "title": "Atherosclerosis Drugs Market Size is expected to reach USD 26.9 Billion by 2032, registering a CAGR of 2.8% from 2023 to 2032",
            "description": "Acumen Research and Consulting recently published report titled \u201cAtherosclerosis Drugs Market Forecast, 2023 - 2032\u201d Acumen Research and Consulting recently published report titled \u201cAtherosclerosis Drugs Market Forecast, 2023 - 2032\u201d",
            "url": "https://www.globenewswire.com/news-release/2023/10/02/2752937/0/en/Atherosclerosis-Drugs-Market-Size-is-expected-to-reach-USD-26-9-Billion-by-2032-registering-a-CAGR-of-2-8-from-2023-to-2032.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d",
            "publishedAt": "2023-10-02T15:00:00Z",
            "content": "NEWYORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Atherosclerosis Drugs Market is at the forefront of medical innovation, offering advanced therapeutic solutions for the growing global burden of cardiov\u2026 [+8733 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG",
            "description": "The increase in the chronic lower back pain market size is a direct consequence of the expected launch of potential therapies, along with great competition among various companies and precision approaches that will lead to more effective therapies. LAS VEGAS,\u2026",
            "url": "https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-09-21T21:01:00Z",
            "content": "The increase in the chronic lower back pain market size is a direct consequence of the expected launch of potential therapies, along with great competition among various companies and precision appro\u2026 [+14180 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints",
            "description": "CAHtalyst\u2122 Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adrenal Hyperplasia Key Secondary Endpoint Demonstrated a Statistically Signi\u2026",
            "url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-phase-3-pediatric-study-results-of-crinecerfont-in-children-and-adolescents-for-the-treatment-of-congenital-adrenal-hyperplasia-met-primary-and-key-secondary-endpoints-301947867.html",
            "urlToImage": "https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg?p=facebook",
            "publishedAt": "2023-10-05T11:00:00Z",
            "content": "<ul><li>CAHtalyst Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adrenal Hy\u2026 [+13811 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Comprehensive Analysis of Dynamics and Market Trends in Elderly Nutrition 2023-2030",
            "description": "Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The \"Global Elderly Nutrition Market by Type (Antioxidants, Fibers, Iron), Form (Chewables, Liquid, Powder), Indication, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - For\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/18/2744796/28124/en/Comprehensive-Analysis-of-Dynamics-and-Market-Trends-in-Elderly-Nutrition-2023-2030.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-18T12:43:00Z",
            "content": "Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The \"Global Elderly Nutrition Market by Type (Antioxidants, Fibers, Iron), Form (Chewables, Liquid, Powder), Indication, Distribution - Cumulative Impact of\u2026 [+5874 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Diagnostic Centers Lead End-User Preferences in the Growing Global Head & Neck Cancer Diagnostics Market",
            "description": "Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The \"Global Head & Neck Cancer Diagnostics Market by Diagnostic Method (Bioscopy Screening, Blood Tests, Dental Diagnostic), End User (Diagnostic Centers, Hospitals) - Cumulative Impact of COVID-19, Russia Ukraine Co\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747057/28124/en/Diagnostic-Centers-Lead-End-User-Preferences-in-the-Growing-Global-Head-Neck-Cancer-Diagnostics-Market.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-21T09:33:00Z",
            "content": "Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The \"Global Head &amp; Neck Cancer Diagnostics Market by Diagnostic Method (Bioscopy Screening, Blood Tests, Dental Diagnostic), End User (Diagnostic Center\u2026 [+5288 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Integrase Inhibitors Market, 2023-2030: Efficacy and Safety of Integrase Inhibitors Make Them Key Players in HIV/AIDS Treatment",
            "description": "Dublin, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The \"Integrase Inhibitors Market, By Distribution Channel, By Region, By End User, and By Geography- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030\" report has been added to ResearchAndMarkets.com's offe\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/27/2750205/28124/en/Global-Integrase-Inhibitors-Market-2023-2030-Efficacy-and-Safety-of-Integrase-Inhibitors-Make-Them-Key-Players-in-HIV-AIDS-Treatment.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-27T10:43:00Z",
            "content": "Dublin, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The \"Integrase Inhibitors Market, By Distribution Channel, By Region, By End User, and By Geography- Size, Share, Outlook, and Opportunity Analysis, 2023 - \u2026 [+5211 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Fortune Business Insights",
            "title": "Contraceptive Drugs Market Size to Surpass USD 31.30 Billion by 2030, exhibiting a CAGR of 7.7%",
            "description": "As per the report by Fortune Business Insights, the global contraceptive drugs market size is projected to reach USD 31.30 Billion by 2030, at a CAGR of 7.7% during the forecast period As per the report by Fortune Business Insights, the global contraceptive d\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/25/2748478/0/en/Contraceptive-Drugs-Market-Size-to-Surpass-USD-31-30-Billion-by-2030-exhibiting-a-CAGR-of-7-7.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/05408ba1-26b1-4fdd-8f48-1af4df373348",
            "publishedAt": "2023-09-25T10:38:00Z",
            "content": "Pune, India, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The contraceptive drugs market size was valued at USD 17.50 billion in 2022 and is slated to reach a valuation of USD 18.57 billion in 2023 and it is e\u2026 [+8025 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "COMPASS Pathways",
            "title": "COMPASS Pathways appoints Daphne Karydas to its Board of Directors",
            "description": "LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (\u201cCOMPASS\u201d), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to it\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/18/2745209/0/en/COMPASS-Pathways-appoints-Daphne-Karydas-to-its-Board-of-Directors.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/e61ab9b9-87f6-4418-b0d9-2fd1a7f5f90c",
            "publishedAt": "2023-09-18T20:31:00Z",
            "content": "LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental healt\u2026 [+8056 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Seramount",
            "title": "Seramount Names the 2023 Top 75 Company for Executive Women",
            "description": "L\u2019Or\u00e9al USA Named Number One Company L\u2019Or\u00e9al USA Named Number One Company",
            "url": "https://www.globenewswire.com/news-release/2023/09/19/2745726/0/en/Seramount-Names-the-2023-Top-75-Company-for-Executive-Women.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/5966a0cd-958b-4236-a4a8-06386208ad63",
            "publishedAt": "2023-09-19T13:07:00Z",
            "content": "Washington, DC, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Seramount, a strategic professional services and research firm, revealed its\u00a02023 Top 75 Companies for Executive Women list\u00a0today. Seramount continu\u2026 [+3649 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Vantage Market Research",
            "title": "Pharmaceutical Manufacturing Market Size & Share to Surpass $863.6 Billion by 2030 | Vantage Market Research",
            "description": "WASHINGTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Pharmaceutical Manufacturing Market is poised for growth due to various factors, such as the increase in demand for pharmaceutical products, advancements in technology, and a ri\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/10/2757611/0/en/Pharmaceutical-Manufacturing-Market-Size-Share-to-Surpass-863-6-Billion-by-2030-Vantage-Market-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b992ad70-52a5-4308-9ec3-ec32ebfecaee",
            "publishedAt": "2023-10-10T13:14:00Z",
            "content": "WASHINGTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Pharmaceutical Manufacturing Market is poised for growth due to various factors, such as the increase in demand for p\u2026 [+18397 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DataHorizzon Research",
            "title": "Immunotherapy Drugs Market To Reach USD 235.4 Billion By 2032, Says DataHorizzon Research",
            "description": "Detailed report on immunotherapy drugs market. The growing prevalence of cancer cases has boosted the demand for the immunotherapy drugs. Detailed report on immunotherapy drugs market. The growing prevalence of cancer cases has boosted the demand for the immu\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/12/2759217/0/en/Immunotherapy-Drugs-Market-To-Reach-USD-235-4-Billion-By-2032-Says-DataHorizzon-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/ee0903f0-279f-4537-8a89-666461d3d324",
            "publishedAt": "2023-10-12T12:10:00Z",
            "content": "Fort Collins, Colorado, Oct. 12, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, the\u00a0immunotherapy drugs market size was valued at USD 121.5 Billion in 2022 and is expected to reach USD \u2026 [+5031 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Environmental Sustainability and Technological Advancements Drive Electric Aircraft Market to Over $9.5 Billion in 2023, with Strong Growth Expected Through 2033",
            "description": "Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The \"AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/15/2743782/28124/en/Environmental-Sustainability-and-Technological-Advancements-Drive-Electric-Aircraft-Market-to-Over-9-5-Billion-in-2023-with-Strong-Growth-Expected-Through-2033.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-15T08:13:00Z",
            "content": "Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The \"AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global AI-Enabl\u2026 [+5854 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Brainy Insights Pvt. Ltd.",
            "title": "Global Ulcerative Colitis Drug Market Size: Poised to Exceed USD 10.59 Billion by 2028 with a 5.03% CAGR",
            "description": "According to The Brainy Insights, the global ulcerative colitis drug market size is projected to reach USD 10.59 billion by 2028 from its value of USD 7.15 billion in 2020, at a CAGR of 5.03% during the forecast period. Several technological and pharmaceutica\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/20/2746673/0/en/Global-Ulcerative-Colitis-Drug-Market-Size-Poised-to-Exceed-USD-10-59-Billion-by-2028-with-a-5-03-CAGR.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/e0ed2f75-5061-4c4a-a30b-65427e5cc0f4",
            "publishedAt": "2023-09-20T15:00:00Z",
            "content": "Seattle, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The global\u00a0ulcerative colitis drug market is expected to grow from USD 7.15 billion in 2020 to USD 10.59 billion by 2028, at a CAGR of 5.03% during the for\u2026 [+5912 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global High Potency Active Pharmaceutical Ingredients Market 2023-2028: HPAPIs Market Benefits from Government Support and Regulatory Streamlining for Breakthrough Medications",
            "description": "Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The \"Global High Potency Active Pharmaceutical Ingredients Market (2023-2028) by Synthesis, Drug Type, Manufacturer Type, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis\" rep\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/29/2751830/28124/en/Global-High-Potency-Active-Pharmaceutical-Ingredients-Market-2023-2028-HPAPIs-Market-Benefits-from-Government-Support-and-Regulatory-Streamlining-for-Breakthrough-Medications.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-29T09:23:00Z",
            "content": "Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The \"Global High Potency Active Pharmaceutical Ingredients Market (2023-2028) by Synthesis, Drug Type, Manufacturer Type, Applications, and Geography, Compe\u2026 [+4813 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Global Cancer Pain Market 2023-2028: Eli Lilly & Company and Johnson & Johnson at the Forefront of Personalized Pain Management for Cancer Patients",
            "description": "Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The \"Global Cancer Pain Market (2023-2028) by Type, Disease Indication, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/09/28/2750975/28124/en/Global-Cancer-Pain-Market-2023-2028-Eli-Lilly-Company-and-Johnson-Johnson-at-the-Forefront-of-Personalized-Pain-Management-for-Cancer-Patients.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-09-28T09:28:00Z",
            "content": "Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The \"Global Cancer Pain Market (2023-2028) by Type, Disease Indication, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis\" report \u2026 [+5380 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PRNewswire"
            },
            "author": null,
            "title": "Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies",
            "description": "Strategic partnership leverages Capsida's next-generation manufacturing capabilities to enable development of KateTx's gene therapy medicines for muscle and heart diseases THOUSAND OAKS, Calif. and SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- Capsida Biotherapeuti\u2026",
            "url": "https://www.prnewswire.com/news-releases/capsida-biotherapeutics-enters-strategic-collaboration-with-kate-therapeutics-to-manufacture-katetxs-next-generation-gene-therapies-301944700.html",
            "urlToImage": "https://mma.prnewswire.com/media/2095160/Kate_Therapeutics_Logo.jpg?p=facebook",
            "publishedAt": "2023-10-03T11:45:00Z",
            "content": "Strategic partnership leverages Capsida's next-generation manufacturing capabilities to enable development of KateTx's gene therapy medicines for muscle and heart diseases\r\nTHOUSAND OAKS, Calif. and \u2026 [+4351 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Emergen Research",
            "title": "Global Anti-Inflammatory Drugs Market Size to Reach USD 250.08 Billion in 2030 | Emergen Research",
            "description": "Potential pipeline candidates is a key factor driving anti-inflammatory drugs market revenue growth Potential pipeline candidates is a key factor driving anti-inflammatory drugs market revenue growth",
            "url": "https://www.globenewswire.com/news-release/2023/09/14/2743494/0/en/Global-Anti-Inflammatory-Drugs-Market-Size-to-Reach-USD-250-08-Billion-in-2030-Emergen-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/8825ef83-644c-4c64-a208-863167237797",
            "publishedAt": "2023-09-14T15:30:00Z",
            "content": "Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global anti-inflammatory drugs market\r\n size reached USD 111.42 Billion in 2021 and is expected to register a revenue CAGR of 9.3% during the forecas\u2026 [+13252 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Sjogren's Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences",
            "description": "Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/21/2747580/0/en/Sjogren-s-Syndrome-Market-Size-Increase-with-Significant-CAGR-by-2032-Predicts-DelveInsight-Key-Companies-in-the-Market-Resolve-MorphoSys-Novartis-GlaxoSmithKline-Roche-BMS-TearSol.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-09-21T17:00:00Z",
            "content": "New York, USA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sjogren's Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Nova\u2026 [+19305 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Fortune Business Insights",
            "title": "Inflammatory Bowel Disease Treatment Market Size to Surpass USD 37.00 Billion by 2029, exhibiting a CAGR of 5.7%",
            "description": "As per the report by Fortune Business Insights, the global inflammatory bowel disease treatment market size is projected to reach USD 37.00 billion in 2029, at a CAGR of 5.7% during the forecast period, 2022-2029 As per the report by Fortune Business Insights\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/05/2755127/0/en/Inflammatory-Bowel-Disease-Treatment-Market-Size-to-Surpass-USD-37-00-Billion-by-2029-exhibiting-a-CAGR-of-5-7.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/05408ba1-26b1-4fdd-8f48-1af4df373348",
            "publishedAt": "2023-10-05T08:35:00Z",
            "content": "Pune, India, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market\r\n size was valued at USD 23.90 billion in 2021 and projected to grow USD 37.00 billion by 2029, exhibiti\u2026 [+7822 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Visiongain Reports Ltd",
            "title": "Contract Research Organisations (CROs) market is projected to grow at a CAGR of 10.6% by 2033: Visiongain",
            "description": "Visiongain has published a new report entitled Contract Research Organisations (CROs) Market Report 2023-2033: Forecasts by Service (Preclinical, Clinical, Laboratory Services, Consulting Services, Data Management Services), by Therapeutic Area (Oncology, CNS\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/15/2744188/0/en/Contract-Research-Organisations-CROs-market-is-projected-to-grow-at-a-CAGR-of-10-6-by-2033-Visiongain.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/6bdb779b-409b-453a-a1ac-5548f5b2a98e",
            "publishedAt": "2023-09-15T17:18:00Z",
            "content": "Visiongain has published a new report entitled Contract Research Organisations (CROs) Market Report 2023-2033: Forecasts by Service (Preclinical, Clinical, Laboratory Services, Consulting Services, D\u2026 [+11247 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Rising Incidence of Kidney Disorders Boosts Kidney Disease Market: Over 37 Million Americans Affected, Highlighting Growing Demand for Treatment Solutions",
            "description": "Dublin, Oct.  12, 2023  (GLOBE NEWSWIRE) -- The \"Kidney Disease Global Market Report 2023\" report has been added to  ResearchAndMarkets.com's offering. ...",
            "url": "https://www.globenewswire.com/news-release/2023/10/12/2759115/28124/en/Rising-Incidence-of-Kidney-Disorders-Boosts-Kidney-Disease-Market-Over-37-Million-Americans-Affected-Highlighting-Growing-Demand-for-Treatment-Solutions.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-10-12T11:13:00Z",
            "content": "Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The \"Kidney Disease Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.\r\nThe global kidney diseases market is experiencing\u2026 [+10016 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Investors in denial",
            "description": "(marketscreener.com) Things aren\u0092t great on stocks markets at the moment, with Wall Street coming off a third consecutive week of declines. After the recession that everyone talks about but never sees, investors are focusing on the Fed pivot that everyone tal\u2026",
            "url": "https://www.marketscreener.com/news/latest/Investors-in-denial--44915586/",
            "urlToImage": "https://img.zonebourse.com/reuters/2023-08/2023-08-15T205705Z_1_LYNXMPEJ7E0T8_RTROPTP_3_USA-STOCKS.JPG",
            "publishedAt": "2023-09-25T13:33:44Z",
            "content": "Things aren't great on stocks markets at the moment, with Wall Street coming off a third consecutive week of declines. After the recession that everyone talks about but never sees, investors are focu\u2026 [+7040 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "The Insight Partners",
            "title": "Artwork Management Software Market worth $1.12 Billion by 2030 - Exclusive Report by The Insight Partners",
            "description": "The Artwork Management Software Market is growing at a CAGR of 9.4% from 2022 to 2030. The Artwork Management Software Market is growing at a CAGR of 9.4% from 2022 to 2030.",
            "url": "https://www.globenewswire.com/news-release/2023/09/29/2752045/0/en/Artwork-Management-Software-Market-worth-1-12-Billion-by-2030-Exclusive-Report-by-The-Insight-Partners.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/efd8c9da-ac10-487a-a083-ec8f33cad35e",
            "publishedAt": "2023-09-29T13:26:00Z",
            "content": "Pune, India., Sept. 29, 2023 (GLOBE NEWSWIRE) -- According to a new report on Artwork Management Software Market\r\n Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Oppo\u2026 [+9333 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Prophecy Market insights",
            "title": "[Newly launched] Orphan Drugs Market is estimated to be US$ 869.6 billion by 2030 with a CAGR of 10.4% during the forecast period \u2013 By PMI",
            "description": "Prophecy Market Insights latest research report on the Orphan Drugs Market provides a comprehensive analysis of the current market scenario, growth opportunities, challenges, and emerging trends. The report offers insights into the market's size and share, ke\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/12/2741998/0/en/Newly-launched-Orphan-Drugs-Market-is-estimated-to-be-US-869-6-billion-by-2030-with-a-CAGR-of-10-4-during-the-forecast-period-By-PMI.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/20cb1ee4-d3e9-4331-b534-eae221b5f383",
            "publishedAt": "2023-09-12T17:30:00Z",
            "content": "Covina , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Introduction: \r\nOrphan drugs\r\n are used to treat and diagnose an orphan disease which can be serious or even cause life-threating. Orphan drugs are not dev\u2026 [+6087 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Neumora Therapeutics, Inc.",
            "title": "Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development",
            "description": "Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep ex\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/10/2757307/0/en/Neumora-Therapeutics-Announces-Appointment-of-Robert-Lenz-M-D-Ph-D-as-Executive-Vice-President-Head-of-Research-and-Development.html",
            "urlToImage": null,
            "publishedAt": "2023-10-10T11:00:00Z",
            "content": "WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the\u2026 [+4867 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Market.Us",
            "title": "Medical Aesthetics Market | Non-Invasive segment to be largest dominated procedure type - Market.us",
            "description": "\"The key to market success lies in embracing technological progress and directing efforts towards the development of advanced, minimally intrusive technology.\" \"The key to market success lies in embracing technological progress and directing efforts towards t\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/15/2743909/0/en/Medical-Aesthetics-Market-Non-Invasive-segment-to-be-largest-dominated-procedure-type-Market-us.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/80497cfc-1ece-42b4-9027-27841cdcb680",
            "publishedAt": "2023-09-15T11:30:00Z",
            "content": "New York, Sept. 15, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the global Medical Aesthetics Market\u00a0Size accounted for USD\u00a015.3 Million in 2022 and is estimated to garner a market size of USD\u00a05\u2026 [+11904 chars]"
        }
    ]
}